MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
+0.050
+2.86%
Closed 16:00 07/14 EDT
OPEN
1.760
PREV CLOSE
1.750
HIGH
1.810
LOW
1.710
VOLUME
468.24K
TURNOVER
--
52 WEEK HIGH
3.660
52 WEEK LOW
0.8214
MARKET CAP
124.13M
P/E (TTM)
-0.6728
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABUS stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 1.000.

EPS

ABUS News

More
Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy?
Insider Monkey · 06/16 01:18
Arbutus to Present at Jefferies Virtual Healthcare Conference
WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
GlobeNewswire · 05/27 12:00
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
Mid-Afternoon Market Update: NASDAQ Rises 70 Points; ShiftPixy Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.18% to 24552.63 while the NASDAQ rose 0.76% to 9304.91. The S&P also rose, gaining 0.21% to 2960.01.
Benzinga · 05/19 18:33
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) jumped 85.8% to $1.43. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/19 16:48
Mid-Day Market Update: Crude Oil Up 2%; Bellerophon Therapeutics Shares Plummet
Midway through trading Tuesday, the Dow traded down 0.11% to 24569.40 while the NASDAQ rose 0.73% to 9302.01. The S&P also rose, gaining 0.19% to 2959.67.
Benzinga · 05/19 16:23
UPDATE: Wedbush Upgrades Arbutus Biopharma To Outperform, Raises Target To $4 'following positive 12-Week 60 mg single-dose data for AB-729 in chronic HBV patients'
Benzinga · 05/19 16:14
P/E Ratio Insights for Arbutus Biopharma
Benzinga · 05/19 16:11

Industry

Pharmaceuticals
+1.34%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.
More

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.